Back to search
FDAFDA · Food and drugs·Recall number D-0096-2025

Diltiazem Hydrochloride Extended-Release Capsules, USP 60 mg, Twice-a-Day Dosage, Rx Only, 100 Capsules per bottle, Mfd for: Northstar Rx LLC, Memphis, TN, Mfd by: Glenmark Pharmaceuticals Limited, Pithampur, Madhya Pradesh India, NDC 16714-553-01.

Published December 11, 2024 · Recall initiated: November 1, 2024

Summary

FDA records drug Class II recall D-0096-2025, published December 11, 2024 and initiated November 1, 2024. Recalling firm: Glenmark Pharmaceuticals Inc., USA; Status: Ongoing; Reported quantity: 5232 bottles; Lot: Lot #: 17222544, Exp 11/30/2024. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

cGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Glenmark Pharmaceuticals Inc., USA
Distributor
Nationwide in the USA
Lot
Lot #: 17222544, Exp 11/30/2024.
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Diltiazem Hydrochloride Extended-Release Capsules, USP 60 mg, Twice-a-Day Dosage, Rx Only, 100 Capsules per bottle, Mfd for: Northstar Rx LLC, Memphis, TN, Mfd by: Glenmark Pharmaceuticals Limited, Pithampur, Madhya Pradesh India, NDC 16714-553-01. recalled?

Yes. FDA published recall D-0096-2025 on December 11, 2024. Reported hazard: cGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.

What should I do if I have this product?

Voluntary: Firm initiated · Letter